Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial in those with methylthioadenosine phosphorylase (MTAP)-deleted solid tumours ...

About 15% of all cancers have co-deletion of both the MTAP and CDKN2A genes, which results in sensitization to MAT2A inhibitors, thus opening a therapeutic window in these cancer types. MAT2A ...

mTap lets you effortlessly create and share dynamic digital business cards that enhance networking capabilities and showcase professionalism, whether you’re an individual, a small business, a ...

Tango Therapeutics is a high-risk, high-reward opportunity in the field of PRMT5-inhibitor drugs targeting MTAP-deleted cancers. Read more on TNGX stock here.

This marks a significant step in targeting tumors like pancreatic and mesothelioma cancers, ... a promising small molecule inhibitor aimed at treating advanced solid tumors with MTAP gene deficiency.

GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led Phase II trial. The NERO study (NCT05455424) investigated the ...

mTap was created to bridge the gap between traditional networking methods and the demands of a digital-first world. The platform aims to replace outdated paper business cards with a streamlined, ...

mTap Digital Business Card. One of the best features for me was the ability to follow up and send personalised messages after you have shared your details with an individual.

The first-in-human Phase 1a/b clinical trial of GTA182 is an open-label, multicenter study involving dose escalation and dose expansion. The study will enroll patients with MTAP-null solid tumors ...

The mTap digital business card offers a sleek and modern solution to elevate your networking game. 9 Reasons Why mTap is the Networking Game-Changer You Need. Produced by: Pranav Dixit.